The sBLA for the pediatric indication is supported by data from the randomized, double-blind, placebo-controlled, phase 3 SPACE trial.

CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues.

HealthDay News — Among US adolescents, current medical use of prescription stimulants for attention-deficit/hyperactivity disorder (ADHD) increased between 2005 and 2023, while nonmedical use ...

HealthDay News — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according to ...

HealthDay News — The US Preventive Services Task Force (USPSTF) recommends screening adults for unhealthy alcohol use and providing brief behavioral counseling interventions for those engaged in risky ...

The move would revoke abortion access for vets and eligible family members expanded in 2022 under the Biden administration. The expansion included states that ban abortion.

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

HealthDay News — Having a supratherapeutic international normalized ratio (INR) while taking warfarin does not significantly increase the risk for brain bleeding after blunt head trauma in older ...

Most life-years saved were among people aged 60 years or older; estimates are more conservative than those that focused on the first year of vaccination ...

The gender pay gap for US physicians hit 26% in 2024, which was an increase from the 23% pay gap observed in 2023, according to Doximity’s Physician Compensation Report 2025.

“We saw that critical-care management of brain swelling, along with immune modulating therapies such as plasma exchange and intravenous immunoglobin, appeared helpful for patients who recovered,” ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for lisocabtagene maraleucel (liso-cel) for adults with relapsed or ...